TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05529706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Program
Description: The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
Study: NCT06397729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List Control
Description: Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT Tool
Description: PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
Study: NCT06297460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systems Training for Emotional Predictability & Problem Solving (STEPPS)
Description: STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
Study: NCT05368519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brijjit®
Description: Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brijjit®
Description: Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
Study: NCT05727332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Sprint Training
Description: A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
Study: NCT05833542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education materials
Description: Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-provider decision tool
Description: Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
Study: NCT06252415

Intervention type: BIOLOGICAL
Intervention: foetal amniotic fluid sample
Description: At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: 2 x 5ml blood EDTA tubes for both parents
Study: NCT05981430

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplant
Description: Active comparator will receive infusion of 125mL fecal suspension via enema

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham fecal microbiota transplant
Description: Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
Study: NCT06252415

Intervention type: OTHER
Intervention: semi-structured online interviews
Description: 25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
Study: NCT05258292

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Glucose levels will be measured using continuous glucose monitoring

Intervention type: DRUG
Intervention: Insulin
Description: Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)

Intervention type: OTHER
Intervention: Premenstrual symptoms
Description: Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool

Intervention type: OTHER
Intervention: Ovulation kits
Description: Ovulation testing will be done using ovulation kits

Intervention type: DEVICE
Intervention: Fitbit Inspire 2
Description: Physical activity will be assessed using the Fitbit Inspire 2

Intervention type: OTHER
Intervention: Keenoa
Description: Food intake will be assessed using the Keenoa phone application

Intervention type: OTHER
Intervention: Menstrual cycle
Description: The application My Calendar will be used to record information on the menstrual cycle
Study: NCT05229666

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Challenge
Description: Cognitive challenge delivered via computer.
Study: NCT06195007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior.
Study: NCT05500521

Intervention type: DIAGNOSTIC_TEST
Intervention: Caloric irrigation
Description: In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.

Intervention type: DIAGNOSTIC_TEST
Intervention: Caloric irrigation
Description: In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.

Intervention type: DIAGNOSTIC_TEST
Intervention: vHIT
Description: This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.

Intervention type: DIAGNOSTIC_TEST
Intervention: vHIT
Description: This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.

Intervention type: DIAGNOSTIC_TEST
Intervention: VEMP
Description: Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).

Intervention type: DIAGNOSTIC_TEST
Intervention: VEMP
Description: Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
Study: NCT06564935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heptaminol Hydrochloride
Description: heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
Study: NCT01296204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB4 antibody-Iodine 131
Description: Injection of an antibody after labelling with Iodine 131
Study: NCT06277050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Therapy with Toripalimab and Capecitabine
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance Therapy with Capecitabine
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
Study: NCT05188014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luteal Phase Aerobic Exercise
Description: Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follicular Phase Aerobic Exercise
Description: Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
Study: NCT05156528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine
Description: Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
Study: NCT06517953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: An orally first-generation EGFR inhibitior.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib
Description: An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
Study: NCT06013345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: analgosedation without secured airway

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: analgosedation with secured airway

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TIVA with secured airway
Study: NCT04763278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Digit
Description: The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
Study: NCT05880368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient partnership tools
Description: The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
Study: NCT06381648

Intervention type: DIAGNOSTIC_TEST
Intervention: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Description: A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Description: A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Description: A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Description: A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
Study: NCT06449118

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Stress Reduction Program
Description: Mindfulness based-Stress Reduction Program an 8-week program
Study: NCT05870124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nalu Neurostimulation System for PNS
Description: The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Conventional Medical Management is the best standard of care treatment for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Conventional Medical Management is the best standard of care treatment for the patient
Study: NCT06465095

Intervention type: GENETIC
Intervention: Baseline
Description: Measurements and sampling

Intervention type: GENETIC
Intervention: Baseline
Description: Measurements and sampling

Intervention type: GENETIC
Intervention: Baseline
Description: Measurements and sampling
Study: NCT05410223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study: NCT06555224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane Hydration MDPF eye drops
Description: Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
Study: NCT05653037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD4059
Description: Subcutaneously Administered RBD4059 in Healthy Subjects.
Study: NCT05937854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one or two encapsulated tablets of placebo po QD
Study: NCT05473624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: Participants will receive HRS-1167.
Study: NCT04779008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning （RIPC）
Description: Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study: NCT05653037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthys Subject.
Study: NCT05256537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omission of the drug mycophenolate mofetil
Description: Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
Study: NCT06493526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.
Description: Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
Study: NCT05360784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Description: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Description: Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Study: NCT05938062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
Description: the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
Description: the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
Study: NCT04747080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.